Phase II randomized, double-blind, parallel-group, adaptive and multicenter study to evaluate the non-inferiority of the immune response in adults of the prophylactic anti-SARS-CoV-2 vaccine candidate FINLAY-FR-1 compared to FINLAY-FR-02 in Heterologous Two Dose and One Boost Dose Schedules with FINLAY-FR-1A. (COVID-19) - SOBERANA CENTRO

Start Date26 Jul 2021

Sponsor / Collaborator

Finlay Vaccine Institute

RPCEC00000338 / CompletedPhase 1IIT

Phase I, randomized, double-blind and adaptive study to evaluate the safety, reactogenicity and explore the immunogenicity of different formulations of the Prophylactic Vaccine Candidates against SARS - CoV - 2, FINLAY- FR-1 and FINLAY- FR-1A (COVID-19). - SOBERANA 01A

Start Date19 Oct 2020

Sponsor / Collaborator

Finlay Vaccine Institute

RPCEC00000332 / CompletedPhase 1/2IIT

Phase I / II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule. (COVID-19) - SOBERANA 01

Start Date24 Aug 2020

Sponsor / Collaborator

Finlay Vaccine Institute

100 Clinical Results associated with FINLAY-FR1 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute)

100 Translational Medicine associated with FINLAY-FR1 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute)

100 Patents (Medical) associated with FINLAY-FR1 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute)

Literatures (Medical) associated with FINLAY-FR1 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute)

01 Mar 2022·Vaccine

A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity

Article

Author: Martínez-Pérez, Marisel ; Paredes-Moreno, Beatriz ; Bergado-Báez, Gretchen ; Valenzuela-Silva, Carmen ; Tamayo-Rodríguez, Maura ; Chappi-Estévez, Yanet ; Díaz-Machado, Alina ; Perez-Nicado, Rocmira ; Suárez-Batista, Anamary ; García-Rivera, Dagmar ; Ochoa-Azze, Rolando ; Pérez-Rodríguez, Sonia ; Rubino-Moreno, Jorman ; Martín-Trujillo, Alis ; González-Mugica, Raúl ; Valdés-Balbín, Yury ; Verez-Bencomo, Vicente ; Rodríguez-Noda, Laura ; Climent-Ruiz, Yanet ; Alberto González-Delgado, Carlos ; Sánchez-Ramírez, Belinda ; Pi-Estopiñán, Franciscary ; de la Caridad Rodríguez-González, Meiby ; Chen, Guang-Wu ; Dubed-Echevarría, Marta ; Teresa Pérez-Guevara, María ; Hernández-García, Tays ; Amoroto-Roig, Mayté

BACKGROUNDThe Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is the target for many COVID-19 vaccines. Here we report results for phase I clinical trial of two COVID-19 vaccine candidates based on recombinant dimeric RBD (d-RBD).METHODSWe performed a randomized, double-blind, phase I clinical trial in the National Centre of Toxicology in Havana. Sixty Cuban volunteers aged 19-59 years were randomized into three groups (20 subjects each): 1) FINLAY-FR-1 (50 µg d-RBD plus outer membrane vesicles from N. meningitidis); 2) FINLAY-FR-1A-50 (50 µg d-RBD, three doses); 3) FINLAY-FR-1A-25 (25 µg d-RDB, three doses). The FINLAY-FR-1 group was randomly divided to receive a third dose of the same vaccine candidate (homologous schedule) or FINLAY-FR-1A-50 (heterologous schedule). The primary outcomes were safety and reactogenicity. The secondary outcome was vaccine immunogenicity. Humoral response at baseline and following each vaccination was evaluated using live-virus neutralization test, anti-RBD IgG ELISA and in-vitro neutralization test of RBD:hACE2 interaction.RESULTSMost adverse events were of mild intensity (63.5%), solicited (58.8%), and local (61.8%); 69.4% with causal association with vaccination. Serious adverse events were not found. The FINLAY-FR-1 group reported more subjects with adverse events than the other two groups. After the third dose, anti-RBD seroconversion was 100%, 94.4% and 90% for the FINLAY-FR-1, FINLAY-FR-1A-50 and FINLAY-FR-1A-25 respectively. The in-vitro inhibition of RBD:hACE2 interaction increased after the second dose in all formulations. The geometric mean neutralizing titres after the third dose rose significantly in the group vaccinated with FINLAY-FR-1 with respect to the other formulations and the COVID-19 Convalescent Serum Panel. No differences were found between FINLAY-FR-1 homologous or heterologous schedules.CONCLUSIONSVaccine candidates were safe and immunogenic, and induced live-virus neutralizing antibodies against SARS-CoV-2. The highest values were obtained when outer membrane vesicles were used as adjuvant.TRIAL REGISTRYhttps://rpcec.sld.cu/en/trials/RPCEC00000338-En.

100 Deals associated with FINLAY-FR1 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	CU	Finlay Vaccine Institute	24 Aug 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

FINLAY-FR1 anti-SARS-CoV-2 Vaccine(Finlay Vaccine Institute)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation